Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant

被引:80
作者
Glück, R [1 ]
Mischler, R [1 ]
Durrer, P [1 ]
Fürer, E [1 ]
Lang, AB [1 ]
Herzog, C [1 ]
Cryz, SJ [1 ]
机构
[1] Swiss Serum & Vaccine Inst, BERNA, CH-3018 Bern, Switzerland
关键词
D O I
10.1086/315337
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A trivalent influenza virosome vaccine containing hemagglutinin and Escherichia coli heat-labile toxin (HLT) was administered intranasally to young adults and elderly subjects. Symptoms that followed immunization were mild and transient. A significant increase in serum hemagglutination inhibition (HI) antibody was noted for the 3 vaccine strains. There was no significant difference in postimmunization geometric mean titers or seroconversion rates between age groups. The percentage of subjects attaining protective HI titers (greater than or equal to 40%) was comparable in both groups for the A/Bayern (P = .5) and B/Beijing (P = .3) strains but was higher among young adults (92.2%) versus elderly subjects (76.5%; P = .057) for the A/Wuhan strain. The proportion of subjects with nonprotective baseline titers who attained protective levels after immunization was similar in both age groups for the A/Bayern and B/Beijing components, For the A/Wuhan component, significantly (P = .017) more young adults achieved protective titers versus elderly subjects (85.7% and 53.8%, respectively). Vaccination evoked a significant (P < .005) increase in anti-HLT antibody titers.
引用
收藏
页码:1129 / 1132
页数:4
相关论文
共 16 条
  • [1] [Anonymous], 1986, OPTIONS CONTROL INFL
  • [2] The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
    Belshe, RB
    Mendelman, PM
    Treanor, J
    King, J
    Gruber, WC
    Piedra, P
    Bernstein, DI
    Hayden, FG
    Kotloff, K
    Zangwill, K
    Iacuzio, D
    Wolff, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) : 1405 - 1412
  • [3] Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients
    Conne, P
    Gauthey, L
    Vernet, P
    Althaus, B
    Que, JU
    Finkel, B
    Gluck, R
    Cryz, SJ
    [J]. VACCINE, 1997, 15 (15) : 1675 - 1679
  • [4] Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: Role of the A subunit
    deHaan, L
    Holtrop, M
    Verweij, WR
    Agsteribbe, E
    Wilschut, J
    [J]. VACCINE, 1996, 14 (04) : 260 - 266
  • [5] MUTANTS OF ESCHERICHIA-COLI HEAT-LABILE TOXIN LACKING ADP-RIBOSYLTRANSFERASE ACTIVITY ACT AS NONTOXIC, MUCOSAL ADJUVANTS
    DOUCE, G
    TURCOTTE, C
    CROPLEY, I
    ROBERTS, M
    PIZZA, M
    DOMENGHINI, M
    RAPPUOLI, R
    DOUGAN, G
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) : 1644 - 1648
  • [6] Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins
    Giannasca, PJ
    Boden, JA
    Monath, TP
    [J]. INFECTION AND IMMUNITY, 1997, 65 (10) : 4288 - 4298
  • [7] IMMUNOGENICITY OF NEW VIROSOME INFLUENZA VACCINE IN ELDERLY PEOPLE
    GLUCK, R
    MISCHLER, R
    FINKEL, B
    QUE, JU
    SCARPA, B
    CRYZ, SJ
    [J]. LANCET, 1994, 344 (8916) : 160 - 163
  • [8] Glück U, 1999, J VIROL, V73, P7780
  • [9] Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
    Hashigucci, K
    Ogawa, H
    Ishidate, T
    Yamashita, R
    Kamiya, H
    Watanabe, K
    Hattori, N
    Sato, T
    Suzuki, Y
    Nagamine, T
    Aizawa, C
    Tamura, S
    Kurata, T
    Oya, A
    [J]. VACCINE, 1996, 14 (02) : 113 - 119
  • [10] THE ADJUVANT EFFECT OF VIBRIO-CHOLERAE AND ESCHERICHIA-COLI HEAT-LABILE ENTEROTOXINS IS LINKED TO THEIR ADP-RIBOSYLTRANSFERASE ACTIVITY
    LYCKE, N
    TSUJI, T
    HOLMGREN, J
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (09) : 2277 - 2281